Tirzepatide improves CV outcomes in obesity-related HFpEF, regardless of CKD
ACC.25 – In SUMMIT among patients with HFpEF and obesity, the treatment effect of tirzepatide on clinical outcomes was not modified by CKD.
This summary is based on the presentation of Milton Packer, MD (Dallas, TX, USA) at the ACC.25 Scientific Session - Tirzepatide In Patients With Heart Failure With Preserved Ejection Fraction, Obesity And Chronic Kidney Disease: The Summit Trial.
Introduction and methods
There is substantial overlap of HFpEF, obesity and central adiposity, and CKD in the population. The SUMMIT trial previously demonstrated that tirzepatide, a dual GIP/GLP-1RA, reduces the composite of cardiovascular mortality or worsening HF events in patients with HFpEF and obesity. This analysis of SUMMIT focused on the triad of HFpEF, obesity and CKD, and evaluated whether the effects of tirzepatide on clinical outcomes is modified by CKD.
In SUMMIT, 731 patients with HFpEF and obesity were randomized to tirzepatide or placebo. The patient population was enriched for patients at high risk of events, and one of the enrichment criteria was HF decompensation within 12 months or eGFR <70 mL/min/1.73m². Median follow-up period was 104 (IQR: 66–126) weeks. The primary endpoints were a composite of cardiovascular mortality or worsening HF events, and the change in KCCQ- Clinical Summary Score (CSS) at 52 weeks.
Main results
- The treatment effect of tirzepatide on the primary endpoints and other key secondary outcomes was consistent regardless of the presence or absence of CKD (all P for interaction>0.05).
- Compared with placebo, tirzepatide improved eGFR and reduced albuminuria at 52 weeks, regardless of CKD (all P for interaction>0.05).
Conclusion
In this analysis of SUMMIT, tirzepatide reduced the risk of the composite of cardiovascular mortality or worsening HF events, and KCCQ-CSS in patients with HFpEF and obesity, regardless of CKD.
- Our reporting is based on the information provided at the ACC.25 Scientific Session -